A Multi-center, Prospective, Open-label, Randomized Study to Explore Efficacy and Safety of Baricitinib in Refractory Intestinal Behcets Syndrome Patients
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Adalimumab (Primary) ; Baricitinib (Primary)
- Indications Behcet's syndrome
- Focus Therapeutic Use
Most Recent Events
- 04 Mar 2025 New trial record